Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Personal Author:
Moline, Heidi L. ; Whitaker, Michael ; Deng, Li ; Rhodes, Julia C. ; Milucky, Jennifer ; ... More +
Moline, Heidi L. ; Whitaker, Michael ; Deng, Li ; Rhodes, Julia C. ; Milucky, Jennifer ; Pham, Huong ; Patel, Kadam ; Anglin, Onika ; Reingold, Arthur ; Chai, Shua J. ; Alden, Nisha B. ; Kawasaki, Breanna ; Meek, James ; Yousey-Hindes, Kimberly ; Anderson, Evan J. ; Farley, Monica M. ; Ryan, Patricia A. ; Kim, Sue ; Nunez, Val Tellez ; Como-Sabetti, Kathryn ; Lynfield, Ruth ; Sosin, Daniel M. ; McMullen, Chelsea ; Muse, Alison ; Barney, Grant ; Bennett, Nancy M. ; Bushey, Sophrena ; Shiltz, Jessica ; Sutton, Melissa ; Abdullah, Nasreen ; Talbot, H. Keipp ; Schaffner, William ; Chatelain, Ryan ; Ortega, Jake ; Murthy, Bhavini Patel ; Zell, Elizabeth ; Schrag, Stephanie J. ; Taylor, Christopher ; Shang, Nong ; Verani, Jennifer R. ; Havers, Fiona P. Less -
Description:
Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these vaccines have high efficacy against symptomatic disease, including moderate to severe illness (1-3). In addition to clinical trials, real-world assessments of COVID-19 vaccine effectiveness are critical in guiding vaccine policy and building vaccine confidence, particularly among populations at higher risk for more severe illness from COVID-19, including older adults. To determine the real-world effectiveness of the three currently authorized COVID-19 vaccines among persons aged ≥65 years during February 1-April 30, 2021, data on 7,280 patients from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed with vaccination coverage data from state immunization information systems (IISs) for the COVID-NET catchment area (approximately 4.8 million persons). Among adults aged 65-74 years, effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 96% (95% confidence interval [CI] = 94%-98%) for Pfizer-BioNTech, 96% (95% CI = 95%-98%) for Moderna, and 84% (95% CI = 64%-93%) for Janssen vaccine products. Effectiveness of full vaccination in preventing COVID-19-associated hospitalization among adults aged ≥75 years was 91% (95% CI = 87%-94%) for Pfizer-BioNTech, 96% (95% CI = 93%-98%) for Moderna, and 85% (95% CI = 72%-92%) for Janssen vaccine products. COVID-19 vaccines currently authorized in the United States are highly effective in preventing COVID-19-associated hospitalizations in older adults. In light of real-world data demonstrating high effectiveness of COVID-19 vaccines among older adults, efforts to increase vaccination coverage in this age group are critical to reducing the risk for COVID-19-related hospitalization.
Subjects:
[+]
Aged CoronaVirus Infections COVID-19 COVID-19 Vaccines Hospitalization Humans Vaccines, Synthetic
Source:
MMWR Morb Mortal Wkly Rep. 70(32):1088-1093
Pubmed ID:
34383730
Pubmed Central ID:
PMC8360274
Document Type:
Journal Article
Place as Subject:
United States
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:8d050e4870e4274b365e6305cad57bc637f43ed10a3dff8589eee49a39931420
Download URL:
https://stacks.cdc.gov/view/cdc/109808/cdc_109808_DS1.pdf
File Type:

Supporting Files

• 	mm7032e3-F1.gif	gif
  	mm7032e3-F1.jpg	jpeg
  	mm7032e3-F2.gif	gif
  	mm7032e3-F2.jpg	jpeg
  	mm7032e3.nxml	xml

More +